Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Phase 2 Study

NCT07213570 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT07213570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07213570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Phase 2 Study
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Recruiting
Start date
October 16, 2025
Completion date
April 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic